Bosh sahifaBMRN • NASDAQ
add
Biomarin Pharmaceutical Inc
54,09 $
Seans yopilganidan keyin:(0,65%)+0,35
54,44 $
Yopilgan:12-sen, 19:57:43 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
55,91 $
Kunlik diapazon
54,05 $ - 56,07 $
Yillik diapazon
52,93 $ - 85,00 $
Bozor kapitalizatsiyasi
10,39 mlrd USD
Oʻrtacha hajm
2,29 mln
Narx/foyda
16,02
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
CNBC
19 soat oldin
S&P 500 fights for another record — plus, Eaton signals big data center opportunity
0,048%
1,62%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 825,41 mln | 15,92% |
Joriy xarajat | 237,12 mln | -14,50% |
Sof foyda | 240,53 mln | 124,43% |
Sof foyda marjasi | 29,14 | 93,62% |
Har bir ulushga tushum | 1,44 | 50,00% |
EBITDA | 295,45 mln | 101,10% |
Amaldagi soliq stavkasi | 19,25% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,43 mlrd | 16,97% |
Jami aktivlari | 7,46 mlrd | 5,51% |
Jami passivlari | 1,43 mlrd | -19,74% |
Umumiy kapital | 6,03 mlrd | — |
Tarqatilgan aksiyalar | 192,01 mln | — |
Narxi/balansdagi bahosi | 1,78 | — |
Aktivlardan daromad | 9,48% | — |
Kapitaldan daromad | 10,63% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 240,53 mln | 124,43% |
Operatsiyalardan naqd pul | 185,27 mln | 56,00% |
Sarmoyadan naqd pul | -12,59 mln | -113,92% |
Moliyadan naqd pul | -4,60 mln | -136,50% |
Naqd pulning sof oʻzgarishi | 165,01 mln | -26,71% |
Boʻsh pul | 97,11 mln | 1 639,76% |
Haqida
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Tashkil etilgan
mar 1997
Sayt
Xodimlar soni
3 040
